Cargando…

Staging of non-small cell lung cancer (NSCLC)

Staging of non-small lung cancer (NSCLC) uses the TNM classification and is undertaken to identify those patients who are surgical candidates, either initially or after chemo-radiotherapy, and to differentiate patients who will be treated radically from those requiring palliation and to plan radioth...

Descripción completa

Detalles Bibliográficos
Autor principal: Rankin, S C
Formato: Texto
Lenguaje:English
Publicado: e-MED 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693760/
https://www.ncbi.nlm.nih.gov/pubmed/16478697
http://dx.doi.org/10.1102/1470-7330.2006.0004
_version_ 1782131200071041024
author Rankin, S C
author_facet Rankin, S C
author_sort Rankin, S C
collection PubMed
description Staging of non-small lung cancer (NSCLC) uses the TNM classification and is undertaken to identify those patients who are surgical candidates, either initially or after chemo-radiotherapy, and to differentiate patients who will be treated radically from those requiring palliation and to plan radiotherapy fields. Computed tomography and magnetic resonance imaging (MRI) are used in staging and provide anatomical information but have well known limitations in differentiating reactive from malignant nodes, fibrosis from active disease and in defining the extent of invasion. MRI, with its superior soft tissue contrast provides optimal information on brachial plexus and central nervous system involvement. Functional imaging using [2- (18)F]fluorodeoxyglucose positron emission tomography is increasingly being used to provide unique information and when combined with anatomic imaging will provide better staging information for both local disease and the extent of metastases.
format Text
id pubmed-1693760
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher e-MED
record_format MEDLINE/PubMed
spelling pubmed-16937602007-01-31 Staging of non-small cell lung cancer (NSCLC) Rankin, S C Cancer Imaging Article Staging of non-small lung cancer (NSCLC) uses the TNM classification and is undertaken to identify those patients who are surgical candidates, either initially or after chemo-radiotherapy, and to differentiate patients who will be treated radically from those requiring palliation and to plan radiotherapy fields. Computed tomography and magnetic resonance imaging (MRI) are used in staging and provide anatomical information but have well known limitations in differentiating reactive from malignant nodes, fibrosis from active disease and in defining the extent of invasion. MRI, with its superior soft tissue contrast provides optimal information on brachial plexus and central nervous system involvement. Functional imaging using [2- (18)F]fluorodeoxyglucose positron emission tomography is increasingly being used to provide unique information and when combined with anatomic imaging will provide better staging information for both local disease and the extent of metastases. e-MED 2006-01-31 /pmc/articles/PMC1693760/ /pubmed/16478697 http://dx.doi.org/10.1102/1470-7330.2006.0004 Text en Copyright © 2006 International Cancer Imaging Society
spellingShingle Article
Rankin, S C
Staging of non-small cell lung cancer (NSCLC)
title Staging of non-small cell lung cancer (NSCLC)
title_full Staging of non-small cell lung cancer (NSCLC)
title_fullStr Staging of non-small cell lung cancer (NSCLC)
title_full_unstemmed Staging of non-small cell lung cancer (NSCLC)
title_short Staging of non-small cell lung cancer (NSCLC)
title_sort staging of non-small cell lung cancer (nsclc)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693760/
https://www.ncbi.nlm.nih.gov/pubmed/16478697
http://dx.doi.org/10.1102/1470-7330.2006.0004
work_keys_str_mv AT rankinsc stagingofnonsmallcelllungcancernsclc